3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Status:
Terminated
Trial end date:
2015-12-04
Target enrollment:
Participant gender:
Summary
This pilot clinical trial examines how well different imaging biomarkers acquired using
3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to
transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to
conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively
measure tissue structural, functional, cellular, and molecular properties, providing a more
robust, clinically relevant method for assessing cancer response to therapy.